Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Operating Expenses (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Operating Expenses data on record, last reported at $24.0 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 56.52% year-over-year to $24.0 million; the TTM value through Sep 2025 reached $83.6 million, up 37.63%, while the annual FY2024 figure was $64.2 million, 26.81% up from the prior year.
  • Operating Expenses reached $24.0 million in Q3 2025 per ABEO's latest filing, up from $23.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $49.7 million in Q4 2021 and bottomed at $9.0 million in Q2 2022.
  • Average Operating Expenses over 5 years is $17.2 million, with a median of $14.6 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: soared 184.05% in 2021, then tumbled 73.81% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $49.7 million in 2021, then crashed by 73.81% to $13.0 million in 2022, then rose by 1.58% to $13.2 million in 2023, then rose by 26.22% to $16.7 million in 2024, then soared by 44.06% to $24.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $24.0 million in Q3 2025, $23.2 million in Q2 2025, and $19.7 million in Q1 2025.